Long-term survival among men with conservatively treated localized prostate cancer - PubMed (original) (raw)
. 1995 Aug;274(8):626-31.
Affiliations
- PMID: 7637143
Long-term survival among men with conservatively treated localized prostate cancer
P C Albertsen et al. JAMA. 1995 Aug.
Abstract
Objective: To determine age-specific, all-cause mortality, disease-specific mortality, and life expectancy for men aged 65 to 75 years who are treated only with immediate or delayed hormonal therapy for newly diagnosed, clinically localized prostate cancer.
Design: A population-based, retrospective cohort study.
Setting: Patient records were abstracted from 37 acute care hospitals and two Veterans Affairs medical centers in Connecticut. Original pathology slides were sent to a referee pathologist who was blinded to case outcomes.
Subjects: All men identified by the Connecticut Tumor Registry with clinically localized prostate cancer diagnosed in 1971 to 1976 who were aged 65 to 75 years at the time of diagnosis and were untreated or treated with immediate or delayed hormonal therapy.
Main outcome measures: Parametric proportional hazards models incorporating tumor histologic findings, comorbidity, and age at the time of diagnosis to compare cohort survival with that of men in the general population.
Results: After a mean follow-up of 15.5 years, the age-adjusted survival for men with Gleason score 2 to 4 tumors was not significantly different from that of the general population. Maximum estimated lost life expectancy for men with Gleason score 5 to 7 tumors was 4 to 5 years and for men with Gleason score 8 to 10 tumors was 6 to 8 years. Tumor histologic findings and patient comorbidities were powerful independent predictors of survival.
Conclusions: Compared with the general population, men aged 65 to 75 years with conservatively treated low-grade prostate cancer incur no loss of life expectancy. Men with higher-grade tumors (Gleason scores 5 to 10) experience a progressively increasing loss of life expectancy. Case series reports of survival/mortality experienced by men with clinically localized prostate cancer that fail to control for age, tumor histologic features, and comorbidities risk significant bias.
Comment in
- Survival and conservative treatment for localized prostate cancer.
Swanson G. Swanson G. JAMA. 1996 Jan 3;275(1):31; author reply 32. doi: 10.1001/jama.275.1.31b. JAMA. 1996. PMID: 8531276 No abstract available. - Survival and conservative treatment for localized prostate cancer.
Cowen ME, Kattan MW, Miles BJ. Cowen ME, et al. JAMA. 1996 Jan 3;275(1):31-2. doi: 10.1001/jama.1996.03530250035013. JAMA. 1996. PMID: 8531277 No abstract available.
Similar articles
- 20-year outcomes following conservative management of clinically localized prostate cancer.
Albertsen PC, Hanley JA, Fine J. Albertsen PC, et al. JAMA. 2005 May 4;293(17):2095-101. doi: 10.1001/jama.293.17.2095. JAMA. 2005. PMID: 15870412 - Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.
Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Albertsen PC, et al. JAMA. 1998 Sep 16;280(11):975-80. doi: 10.1001/jama.280.11.975. JAMA. 1998. PMID: 9749479 - Prostate cancer and the Will Rogers phenomenon.
Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J. Albertsen PC, et al. J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53. doi: 10.1093/jnci/dji248. J Natl Cancer Inst. 2005. PMID: 16145045 - [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M, Villers A, Richaud P, Prapotnich D, Ruffion A, Grosclaude P. Soulié M, et al. Prog Urol. 2001 Dec;11(6):1195-204. Prog Urol. 2001. PMID: 11859652 Review. French.
Cited by
- Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals.
Cheng E, Lee DH, Tamimi RM, Hankinson SE, Willett WC, Giovannucci EL, Eliassen AH, Stampfer MJ, Mucci LA, Fuchs CS, Spiegelman D. Cheng E, et al. JNCI Cancer Spectr. 2022 Mar 2;6(2):pkac021. doi: 10.1093/jncics/pkac021. JNCI Cancer Spectr. 2022. PMID: 35603853 Free PMC article. - Primary cryotherapy for localised or locally advanced prostate cancer.
Jung JH, Risk MC, Goldfarb R, Reddy B, Coles B, Dahm P. Jung JH, et al. Cochrane Database Syst Rev. 2018 May 30;5(5):CD005010. doi: 10.1002/14651858.CD005010.pub3. Cochrane Database Syst Rev. 2018. PMID: 29845595 Free PMC article. Review. - Ten-Year Trends in Preventive Service Use Before and After Prostate Cancer Diagnosis: A Comparison with Noncancer Controls.
Wallner LP, Slezak JM, Loo RK, Bastani R, Jacobsen SJ. Wallner LP, et al. Perm J. 2017;21:16-184. doi: 10.7812/TPP/16-184. Perm J. 2017. PMID: 29035180 Free PMC article. - Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
Koc G, Turk H, Karabicak M, Un S, Ergani B, Ekin RG. Koc G, et al. Curr Ther Res Clin Exp. 2017 Apr 18;84:50-53. doi: 10.1016/j.curtheres.2017.04.003. eCollection 2017. Curr Ther Res Clin Exp. 2017. PMID: 28761580 Free PMC article. - Patient Preferences for Primary Care Provider Roles in Breast Cancer Survivorship Care.
Wallner LP, Li Y, Furgal AKC, Friese CR, Hamilton AS, Ward KC, Jagsi R, Katz SJ, Hawley ST. Wallner LP, et al. J Clin Oncol. 2017 Sep 1;35(25):2942-2948. doi: 10.1200/JCO.2017.73.1307. Epub 2017 Jul 12. J Clin Oncol. 2017. PMID: 28700276 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical